Drugs / Surzetoclax
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06291220 | Jan 2025 → Jul 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05308654 | May 2022 → Feb 2024 overdue | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06953960 | Jul 2025 → Dec 2030 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Surzetoclax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06953960 ↗ |
| Known as | ABBV-453 | “A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma...” NCT06953960 ↗ |
| Action | Inhibit | “First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma” NCT05308654 ↗ |
| Modality | Small molecule | — CHEMBL6068032 ↗ |
| Route | Oral | “Participants will receive oral ABBV-453 tablets once daily (QD) in 28-day cycles.” NCT05308654 ↗ |
| Target | BCL2 | “First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma” NCT05308654 ↗ |